Diagnostics
-
Waters and BD Biosciences & Diagnostic Solutions to Merge, Forming a Regulated Testing Leader
Waters Corporation and BD (Becton, Dickinson and Company) have announced a definitive agreement to merge BD’s Biosciences & Diagnostic Solutions business with Waters, creating a leading life science and diagnostics company. The deal, valued at $17.5 billion structured as a Reverse Morris Trust, is expected to double Waters’ addressable market to $40 billion and generate $345 million in annualized EBITDA synergies by 2030.The combined company anticipates approximately $6.5 billion in 2025 sales and mid-teens adjusted EPS growth over five years, with the transaction boosting adjusted EPS within the first year.
-
Seer Proteograph Powers Groundbreaking 20,000-Sample Proteomics Study with Korea University, Aiming to Develop AI-Driven Cancer Diagnostics for Young Adults
Seer and Korea University are collaborating on a large-scale study to discover early cancer biomarkers using Seer’s Proteograph ONE Assay and mass spectrometry. This initiative aims to analyze 20,000 plasma samples to identify novel blood-based biomarkers for improved cancer diagnostics, particularly for young adults. The study, supported by the K-Health MIRAE initiative, utilizes AI-driven analytics, promising accelerated analysis, reduced costs, and the potential for earlier cancer detection and improved patient outcomes.
